Literature DB >> 16305068

Pathobiology and cell interactions of platelets in diabetes.

Bernd Stratmann1, Diethelm Tschoepe.   

Abstract

Diabetes is a well-recognised risk factor for atherosclerotic cardiovascular disease and in fact most diabetic patients die from vascular complications. The Diabetes Control and Complications Trial (DCCT) and the U.K. Prospective Diabetes Study (UKPDS) indicate a consistent relationship between hyperglycaemia and the incidence of chronic vascular complications in patients with diabetes. Platelets are essential for haemostasis, and abnormalities of platelet function may cause vascular disease in diabetes. Diabetic patients have hyperreactive platelets with exaggerated adhesion, aggregation and thrombin generation. In summary, the entire coagulation cascade is dysfunctional in diabetes. This review provides a comprehensive overview of the physiological role of platelets in maintaining haemostasis and of the pathophysiological processes that contribute to platelet dysfunction in diabetes and associated cardiovascular diseases, with special emphasis on proteomic approaches and leukocyte-platelet cross-talk.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16305068     DOI: 10.3132/dvdr.2005.001

Source DB:  PubMed          Journal:  Diab Vasc Dis Res        ISSN: 1479-1641            Impact factor:   3.291


  21 in total

Review 1.  [The role of platelets in atherosclerosis, diabetes mellitus, and chronic kidney disease. An attempt at explaining the TREAT study results].

Authors:  Norbert Maurin
Journal:  Med Klin (Munich)       Date:  2010-05-26

Review 2.  Proteomic approaches to dissect platelet function: Half the story.

Authors:  Dmitri V Gnatenko; Peter L Perrotta; Wadie F Bahou
Journal:  Blood       Date:  2006-08-22       Impact factor: 22.113

3.  [Cardial target-organ damage in diabetes].

Authors:  W Motz; W Kerner
Journal:  Internist (Berl)       Date:  2011-05       Impact factor: 0.743

4.  [Characteristics of therapy of acute myocardial infarction in diabetes].

Authors:  W Motz; W Kerner
Journal:  Herz       Date:  2012-05       Impact factor: 1.443

Review 5.  Platelet activation, and antiplatelet targets and agents: current and novel strategies.

Authors:  Yao-Zu Xiang; Ye Xia; Xiu-Mei Gao; Hong-Cai Shang; Li-Yuan Kang; Bo-Li Zhang
Journal:  Drugs       Date:  2008       Impact factor: 9.546

6.  Advanced glycation end products strongly activate platelets.

Authors:  Thomas Gawlowski; Bernd Stratmann; Ruth Ruetter; Christina E Buenting; Barbara Menart; Jürgen Weiss; Helen Vlassara; Theodor Koschinsky; Diethelm Tschoepe
Journal:  Eur J Nutr       Date:  2009-07-26       Impact factor: 5.614

Review 7.  Type 2 diabetes and cardiovascular disease: Have all risk factors the same strength?

Authors:  Iciar Martín-Timón; Cristina Sevillano-Collantes; Amparo Segura-Galindo; Francisco Javier Del Cañizo-Gómez
Journal:  World J Diabetes       Date:  2014-08-15

8.  A Study of Platelet Indices in Type 2 Diabetes Mellitus Patients.

Authors:  Kumari Shilpi; R M Potekar
Journal:  Indian J Hematol Blood Transfus       Date:  2017-05-08       Impact factor: 0.900

9.  [ESC/EASD joint guidelines on diabetes and cardiovascular diseases].

Authors:  Wolfgang Motz; Rolf Dörr
Journal:  Herz       Date:  2009-02       Impact factor: 1.443

10.  Factors contributing to increased platelet reactivity in people with diabetes.

Authors:  David J Schneider
Journal:  Diabetes Care       Date:  2009-04       Impact factor: 17.152

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.